1
|
Simon L, De Taddeo M, Coeurvolan A, Colpaert M, Richard J, Devoisselle JM, Morille M, Marcotte N, Bégu S, Lapinte V. Various lipid anchors on amphiphilic polyoxazolines to reach efficient intracellular delivery. Int J Pharm 2023:123103. [PMID: 37277088 DOI: 10.1016/j.ijpharm.2023.123103] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2023] [Revised: 05/30/2023] [Accepted: 06/01/2023] [Indexed: 06/07/2023]
Abstract
This work aimed at evaluating the potential of amphiphilic polyoxazolines bearing lipid chain called lipopolyoxazolines to reach efficient intracellular delivery. Four lipid chains: linear saturated, linear unsaturated and two branched one of various length were associated to poly(2-methyl-2-oxazoline) block. The evaluation of their physicochemical features and their impact on cell viability and internalization capacity indicated that the linear saturated gathered the highest cell internalization with a good cell viability. Its intracellular delivery capacity was compared to the PEG reference (DSPE-PEG) after being formulated in liposomes and loaded with fluorescent probe. Both POxylated and PEGylated liposomes showed similar characteristics regarding size distribution, drug loading and cell viability. However, their intracellular delivery was dramatically different, with an improved delivery by 30 folds for the POxylated ones. This significantly better performance highlighted the difficulty of PEGylated liposomes to enter the cells by endocytosis, contrary to POxylated liposomes. This study promotes the value of lipopoly(oxazoline) as a lipopoly(ethylene glycol) alternative for effective intracellular delivery and holds great promises for development of nanoformulations for intravenous administration.
Collapse
Affiliation(s)
- L Simon
- ICGM, Univ. Montpellier, CNRS, ENSCM, Montpellier, France
| | - M De Taddeo
- ICGM, Univ. Montpellier, CNRS, ENSCM, Montpellier, France
| | - A Coeurvolan
- ICGM, Univ. Montpellier, CNRS, ENSCM, Montpellier, France
| | - M Colpaert
- ICGM, Univ. Montpellier, CNRS, ENSCM, Montpellier, France
| | - J Richard
- ICGM, Univ. Montpellier, CNRS, ENSCM, Montpellier, France
| | | | - M Morille
- ICGM, Univ. Montpellier, CNRS, ENSCM, Montpellier, France
| | - N Marcotte
- ICGM, Univ. Montpellier, CNRS, ENSCM, Montpellier, France
| | - S Bégu
- ICGM, Univ. Montpellier, CNRS, ENSCM, Montpellier, France
| | - V Lapinte
- ICGM, Univ. Montpellier, CNRS, ENSCM, Montpellier, France.
| |
Collapse
|
2
|
Delivery of doxorubicin loaded P18 conjugated-poly(2-ethyl-oxazoline)-DOPE nanoliposomes for targeted therapy of breast cancer. Toxicol Appl Pharmacol 2021; 428:115671. [PMID: 34391753 DOI: 10.1016/j.taap.2021.115671] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2021] [Revised: 07/31/2021] [Accepted: 08/02/2021] [Indexed: 01/11/2023]
Abstract
Breast cancer, a heterogeneous disease, has the highest incidence rate and is a major cause of death in females worldwide. Drug delivery by using nanotechnology has shown great promise for improving cancer treatment. Nanoliposomes are known to have enhanced accumulation ability in tumors due to prolonged systemic circulation. Peptide 18 (P18), a tumor homing peptide targeting keratin-1 (KRT-1), was previously shown to have high binding affinity towards breast cancer cells. In this study, we investigate the ability of P18 conjugated PEtOx-DOPE nanoliposomes (P18-PEtOx-DOPE) for the targeted delivery of doxorubicin to AU565 breast cancer model. Toxicology studies of PEtOx-DOPE nanoliposomes performed on normal breast epithelial cells (MCF10A), showed minimal toxicity. Doxorubicin delivery by P18-PEtOx-DOPE to AU565 cells induces cytotoxicity in a dose and time dependent manner causing mitotic arrest in G2/M phase at 24 h. Anti-cancer activity of P18-PEtOx-DOPE-DOX nanoliposomes on AU565 cells was detected by Annexin V/PI apoptosis assay. In terms of in vivo antitumor efficacy, P18-PEtOx-DOPE-DOX nanoliposomes administration to AU565 CD-1 nu/nu mice model showed significant decrease in tumor volume suggesting that DOX delivered by these nanoliposomes elicited a strong antitumor response comparable to the free delivery of doxorubicin. Overall, our results offered preclinical proof for the use of P18-PEtOx-DOPE-DOX nanoliposomes in KRT-1+ breast cancer therapy.
Collapse
|